|
|
|
| home > ebr > winter 2003 > the most important current and future data management tasks ahead |
 |
 |
PUBLICATIONS |
European Biopharmaceutical Review
|
| For over 15 years the industry has discussed how to improve the process of capturing data in clinical trials. A lot of time and money have been invested in finding better ways of preparing data for high quality analysis immediately after the last patient has completed the trial. Most important are data standardisation and systems for entering data at the clinics, or systems whereby patients enter self-reported data. There are many good examples of that usage, but there are still a few trials not using paper CRFs and traditional data entry. While the requisite data standards are not in place, they could save time and money. |
Read full article from PDF >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|

 |
Industry Events |
 |
10th-Anniversary Event RFID Journal LIVE! 2012
3-5 April 2012, Walt Disney World Swan and Dolphin Resort, Orlando, Florida
RFID Journal LIVE! 2012, our tenth annual conference and exhibition, is the only event where you can learn how to use RFID technologies to improve your pharmaceutical and medical packaging business, from real-world case studies across all applications, including asset tracking, logistics and transportation, supply chain management, warehouse and inventory management, security and more. Learn from a customized program featuring more than 50 end-user case studies and 8 industry-specific and how-to conference tracks.
More info >> |
|
 |
News and Press Releases |
 |
More safety in drug packaging
In Germany like in the rest of the world, child safety in drug packaging is an issue that has not been properly solved yet. Today, Faubel, the custom label supplier based in Melsungen, provides a safe and economical solution consisting of an innovative safety label which can be affixed to the back of a tablet blister pack like an ordinary sticker.
More info >> |
|
|